BR112022016117A2 - Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22 - Google Patents

Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22

Info

Publication number
BR112022016117A2
BR112022016117A2 BR112022016117A BR112022016117A BR112022016117A2 BR 112022016117 A2 BR112022016117 A2 BR 112022016117A2 BR 112022016117 A BR112022016117 A BR 112022016117A BR 112022016117 A BR112022016117 A BR 112022016117A BR 112022016117 A2 BR112022016117 A2 BR 112022016117A2
Authority
BR
Brazil
Prior art keywords
dimer
prevention
treatment
methods
wound
Prior art date
Application number
BR112022016117A
Other languages
English (en)
Inventor
Yang Zheng
Huang Zhihua
Original Assignee
Evive Biotechnology Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evive Biotechnology Shanghai Ltd filed Critical Evive Biotechnology Shanghai Ltd
Publication of BR112022016117A2 publication Critical patent/BR112022016117A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODOS PARA A PREVENÇÃO OU O TRATAMENTO DE FERIMENTO OU FALHA EM UM ÓRGÃO INDUZIDOS POR VÍRUS COM DÍMERO DE IL-22. A presente invenção se refere ao uso do dímero de IL-22 na prevenção ou no tratamento de ferimento ou falha em um órgão induzidos por vírus, tal como ferimento ou falha do pulmão, sepse, choque séptico ou síndrome de disfunção de múltiplos órgãos (MODS) associada com a infecção por vírus.
BR112022016117A 2020-02-14 2021-02-10 Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22 BR112022016117A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020075408 2020-02-14
CN2020120662 2020-10-13
PCT/CN2021/076519 WO2021160163A1 (en) 2020-02-14 2021-02-10 Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer

Publications (1)

Publication Number Publication Date
BR112022016117A2 true BR112022016117A2 (pt) 2022-10-25

Family

ID=77291386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016117A BR112022016117A2 (pt) 2020-02-14 2021-02-10 Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22

Country Status (10)

Country Link
US (1) US20230079150A1 (pt)
EP (1) EP4103219A4 (pt)
JP (1) JP2023513227A (pt)
KR (1) KR20220164478A (pt)
CN (1) CN116670161A (pt)
AU (1) AU2021218929A1 (pt)
BR (1) BR112022016117A2 (pt)
CA (1) CA3166132A1 (pt)
IL (1) IL295486A (pt)
WO (1) WO2021160163A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
WO2023118896A1 (en) * 2021-12-23 2023-06-29 Subintro Limited Novel antiviral compositions comprising oleic acid
WO2024073007A2 (en) * 2022-09-28 2024-04-04 Napo Pharmaceuticals, Inc. Lyophilized formulation of crofelemer and methods of treatment using the same
US11918505B1 (en) * 2023-09-24 2024-03-05 Baseem Najjar Penis enlargement device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102380091A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103182072B (zh) * 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
EP2903634A1 (en) * 2012-10-03 2015-08-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza
US20160166646A1 (en) * 2013-06-28 2016-06-16 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
CN104623637A (zh) * 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CA3091139A1 (en) * 2018-02-21 2019-08-29 Genentech, Inc. Dosing for treatment with il-22 fc fusion proteins
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome

Also Published As

Publication number Publication date
CN116670161A (zh) 2023-08-29
US20230079150A1 (en) 2023-03-16
EP4103219A1 (en) 2022-12-21
JP2023513227A (ja) 2023-03-30
IL295486A (en) 2022-10-01
AU2021218929A1 (en) 2022-08-25
EP4103219A4 (en) 2024-03-27
CA3166132A1 (en) 2021-08-19
KR20220164478A (ko) 2022-12-13
WO2021160163A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112022016117A2 (pt) Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
UY37592A (es) Compuestos inhibidores del vih
BR112022012625A2 (pt) Compostos moduladores de diacilglicerol quinase
MX2020004838A (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
MX2020004839A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
BR112017023263A2 (pt) compostos antivirais rsv de pirazolo e triazolopirimidina
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
MX2022013749A (es) Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
BR112021017604A2 (pt) Compostos úteis na terapia para hiv
BR112022004861A2 (pt) Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
BR112022004348A2 (pt) Aperfeiçoamentos em ou relacionados a compostos orgânicos
BR112021023845A2 (pt) Complexos macromoleculares de fungicida de ditiocarbamato
EA202091781A1 (ru) Связывающая молекула, обладающая нейтрализующей активностью в отношении коронавируса ближневосточного респираторного синдрома
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112018068462A2 (pt) composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto.
CO2019009216A2 (es) Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
CO2022014031A2 (es) Compuestos para su uso en infecciones víricas
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
BR112019008411A2 (pt) materiais e métodos para o controle de biofilme
MX2023002667A (es) Compuestos y metodos para el tratamiento de infecciones virales.
BR112022018284A2 (pt) Azd1656 para uso no tratamento de pneumonite e/ou miocardite causada por coronavírus